You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 騰盛博藥-B(02137.HK)續升超7%再創階段新高
格隆匯 11-26 11:41
格隆匯11月26日丨騰盛博藥-B(02137.HK)延續強勢行情,再度拉昇漲7.24%,報45.2港元創2個月新高價,總市值325億港元。該股自11月9日以來持續拉昇上漲,區間漲幅高達145%。公司合作研發的新冠藥物BRII-196和BRII-198聯合用藥臨牀Ⅲ期近期已揭盲,這也是目前我國進展最快的抗體藥物,有望12月底前獲得批准附條件上市。與歐美已獲批緊急使用的新冠抗體藥相比,該藥是唯一進行了變異株感染者治療效果評估並獲得數據的。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account